These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34288448)

  • 1. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
    Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
    J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
    Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic heterogeneity of cytogenetically normal AML with mutations of
    Konstandin NP; Pastore F; Herold T; Dufour A; Rothenberg-Thurley M; Hinrichsen T; Ksienzyk B; Tschuri S; Schneider S; Hoster E; Berdel WE; Woermann BJ; Sauerland MC; Braess J; Bohlander SK; Klein HG; Hiddemann W; Metzeler KH; Spiekermann K
    Blood Adv; 2018 Oct; 2(20):2724-2731. PubMed ID: 30337300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
    Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
    Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of acute myeloid leukemia by the revised fourth edition World Health Organization criteria: a retrospective single-institution study with appraisal of the new entities of acute myeloid leukemia with gene mutations in NPM1 and biallelic CEBPA.
    Kansal R
    Hum Pathol; 2019 Aug; 90():80-96. PubMed ID: 31077683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3-ITD and CEBPA Mutations Predict Prognosis in Acute Myelogenous Leukemia Irrespective of Hematopoietic Stem Cell Transplantation.
    Wang H; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    Biol Blood Marrow Transplant; 2019 May; 25(5):941-948. PubMed ID: 30503388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
    Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of cytogenetically normal CEBPA-mutated AML.
    Pastore F; Kling D; Hoster E; Dufour A; Konstandin NP; Schneider S; Sauerland MC; Berdel WE; Buechner T; Woermann B; Braess J; Hiddemann W; Spiekermann K
    J Hematol Oncol; 2014 Sep; 7():55. PubMed ID: 25214041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
    Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
    Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
    Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M; Böttcher M; Thol F; Ganser A; Schlenk R; Wasem J; Neumann A; Pouryamout L
    Ann Hematol; 2014 Aug; 93(8):1279-86. PubMed ID: 24801015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.